Current T-cell engineering approaches redirect patient T cells to tumors by transducing them with antigen-specific T-cell receptors (TCRs) or chimeric antigen receptors (CARs) that target a single antigen 1-3 . However, few truly tumorspecific antigens have been identified, and healthy tissues that express the targeted antigen may undergo T cell-mediated damage [4] [5] [6] [7] . Here we present a strategy to render T cells specific for a tumor in the absence of a truly tumor-restricted antigen. T cells are transduced with both a CAR that provides suboptimal activation upon binding of one antigen and a chimeric costimulatory receptor (CCR) that recognizes a second antigen. Using the prostate tumor antigens PSMA and PSCA, we show that co-transduced T cells destroy tumors that express both antigens but do not affect tumors expressing either antigen alone. This 'tumor-sensing' strategy may help broaden the applicability and avoid some of the side effects of targeted T-cell therapies.
l e t t e r s
Current T-cell engineering approaches redirect patient T cells to tumors by transducing them with antigen-specific T-cell receptors (TCRs) or chimeric antigen receptors (CARs) that target a single antigen [1] [2] [3] . However, few truly tumorspecific antigens have been identified, and healthy tissues that express the targeted antigen may undergo T cell-mediated damage [4] [5] [6] [7] . Here we present a strategy to render T cells specific for a tumor in the absence of a truly tumor-restricted antigen. T cells are transduced with both a CAR that provides suboptimal activation upon binding of one antigen and a chimeric costimulatory receptor (CCR) that recognizes a second antigen. Using the prostate tumor antigens PSMA and PSCA, we show that co-transduced T cells destroy tumors that express both antigens but do not affect tumors expressing either antigen alone. This 'tumor-sensing' strategy may help broaden the applicability and avoid some of the side effects of targeted T-cell therapies.
Adoptive cell therapies using genetically modified autologous T cells have shown efficacy for melanoma and indolent B-cell malignancies [4] [5] [6] [7] . However, their broad applicability is limited by the paucity of truly tumor-specific target antigens. Extra-tumoral antigen expression may indeed result in "on-target, off-tumor" effects. These effects can be acceptable, as is the case with CD19, an antigen expressed in B-cell malignancies and normal B-lineage cells, resulting in B-cell aplasia [5] [6] [7] . In other instances, targeting, for example, carbonic anhydrase IX or human epidermal growth factor receptor 2 (HER2), the side effects may be intolerable and potentially life-threatening 8,9 . Here we present an approach to render engineered T cells specific for a tumor even in the absence of a truly tumor-restricted antigen. T-cell activation requires TCR-or CAR-mediated recognition of one antigen, which in this work is either CD19 or prostate stem cell antigen (PSCA). T-cell costimulation must be independently mediated by a CCR 10 specific for a second antigen, here being prostate-specific membrane antigen (PSMA). This dual-targeting approach facilitates augmented T-cell reactivity against tumors positive for two antigens compared to single-positive tumors, that is, those positive for only one antigen [10] [11] [12] . However, this approach alone fails to prevent T-cell reactivity to single-positive tumors, as we show here. To achieve tumor selectivity, we diminished the efficiency of T-cell activation to a level where it is ineffective in the absence of simultaneous CCR recognition of the second antigen. We hypothesized, and demonstrate below, that T cells expressing suboptimal activation receptors are functionally rescued at the tumor site by a CCR engaging a co-expressed tumor antigen.
To demonstrate that both T-cell activation and costimulation signals can be supplied in vivo using two distinct antigen-specific receptors, we initially evaluated the combination of a CAR that provides a CD3ζ-mediated activation signal upon recognition of the B-cell marker CD19 (19z1) 13 and a CCR specific for PSMA 10, 14 . Based on results showing synergy between CD28 and 4-1BB costimulation 15, 16 , including through their cytoplasmic domains arranged in tandem [17] [18] [19] [20] , we added the 4-1BB cytoplasmic domain to the PSMA-specific CCR P28 (ref. 14) , as described 20 , to generate P28BB ( Supplementary Fig. 1a ). Primary human peripheral blood T cells were retrovirally transduced with 19z1 and/or P28BB, typically yielding expression of both receptors in 45-70% of T cells ( Supplementary  Fig. 1b ). Four groups of T cells were analyzed in all subsequent studies, expressing 19z1, P28BB, 19z1+P28BB or neither (mock).
We first measured the in vitro cytotoxic and proliferative responses of transduced T cells exposed to mouse lymphoma cell line EL4 target cells expressing CD19 and/or PSMA. Cytotoxicity against CD19-expressing target cells was, as expected, imparted by 19z1 expression and was unaltered in the presence of PSMA in all T-cell groups (Fig. 1a) . A quantitative comparison after normalizing to the fraction of 19z1-transduced T cells for the 19z1 and 19z1+P28BB groups and the P28BB-transduced fraction for the P28BB group showed that 19z1 and 19z1+P28BB T cells specifically lysed 40-47% CD19-expressing target cells at the 50:1 effector/target ratio, whereas the P28BB-transduced T cells did not lyse PSMA-expressing targets ( Fig. 1a) . We next examined the proliferation of T cells repeatedly exposed to artificial antigen-presenting cells (AAPCs) expressing CD19 and/or PSMA in the absence of exogenous cytokine. Over 4 weeks, only the 19z1+P28BB T cells underwent robust proliferation (58-fold expansion) when co-cultured on AAPCs expressing both antigens. In contrast, 19z1 or P28BB T cells underwent modest expansion over the first 14 d, as did the 19z1+P28BB T cells exposed to CD19 + PSMA − AAPCs (Fig. 1b) . Further evidence of stronger T-cell l e t t e r s activation in the presence of both antigens was provided by quantitative assessment of cytokine production and the induction of the antiapoptotic molecule Bcl X L, which were maximal in 19z1+P28BB T cells ( Supplementary Fig. 2a,e ).
We then tested the ability of these dual receptor (19z1+P28BB) expressing T cells to eradicate established systemic human prostate tumors in immunocompromised, nonobese diabetic severe/combined immunodeficient (NOD.SCID) Il2rg −/− (NSG) mice. We intravenously infused 2.0 × 10 6 green fluorescent protein/firefly-luciferase (GFP/Luc) expressing PC3 tumor cells that expressed both CD19 and PSMA ( Supplementary Fig. 3 ) followed, 19 d thereafter, by a single intravenous infusion of 1.0 × 10 6 19z1, 19z1+P28BB, P28BB or mock-transduced T cells. Thirty-five days later, mice that received P28BB T cells or mock T cells had to be euthanized owing to tumor burden. Mice treated with 19z1 T cells showed a marked reduction in tumor burden ( Fig. 1c and data not shown). However, mice treated with 19z1+P28BB T cells had undetectable tumor burden. Over 70 d of post-infusion monitoring, the CD19 + tumors eventually relapsed in mice that received 19z1 T cells, whereas complete tumor remission persisted in all mice that received 19z1+P28BB T cells, suggesting that complete tumor eradication had been achieved.
To investigate T-cell activity in a host bearing double-positive as well as single-positive tissues, we established subcutaneous CD19 + PSMA − tumors (a model of single-positive tissues) in the left flanks, CD19 − PSMA + tumors in the right flank and CD19 + PSMA + tumors in the back of the same NSG mice. One week later, we administered 1.0 × 10 6 19z1, P28BB or 19z1+P28BB T cells intravenously. All three tumors progressed in mice that received P28BB T cells, and these mice had to be euthanized within 35 d (Fig. 1d) . In mice treated with 19z1 T cells, the CD19 + PSMA − and CD19 + PSMA + tumors initially underwent substantial reduction in volume but eventually progressed. Mice treated with 19z1+P28BB T cells showed complete eradication of CD19 + PSMA + tumors. However, CD19 + PSMA − tumors were also rejected in these mice more efficiently than in mice bearing only CD19 + PSMA − tumors ( Fig. 1d) . Thus, this dual-targeting combinatorial antigen approach did not restrict T-cell reactivity to double-positive tumors.
To remedy this failure, we reasoned that T-cell activation would have to be minimized, almost to the point of extinction, only to be npg l e t t e r s rescued by simultaneous engagement of the CCR. We thus searched for CARs with diminished activity, and while doing so switched from CD19 and PSMA to a combination of prostate antigens, PSCA and PSMA. We evaluated three PSCA-specific scFvs with different binding affinities for PSCA. We incorporated each PSCA-specific scFv into bispecific PSCA/CD3 antibodies and incubated them with T cells and PSCA-expressing PC3 tumor cells to quantify tumor cell lysis (Fig. 2a) . PSCA/CD3 bispecific antibody containing the CAR Hzl lysed tumor cells 1,000-to 10,000 fold more efficiently than antibody containing the CAR Lz1, even in picogram quantities. We then used these scFvs to construct CARs by linking them to CD3ζ cytoplasmic domains. As expected, T cells expressing the different CARs showed different activities in cytotoxicity assays (Fig. 2b) . Hz1 and Mz1 CARs directed moderate lysis of PSCA + targets (20% specific lysis at the 50:1 effector/target ratio), whereas the Lz1 CAR only reached 10% specific lysis, qualifying it as a suboptimal antigen receptor. This hierarchy was further confirmed in cytokine release assays using T cells expressing each PSCA CAR together with the P28BB CCR ( Supplementary  Fig. 2b-d) .
T cells transduced with 19z1 and Hz1 CARs produced relatively high amounts of T-helper type 1 (T H 1) and T H 2 cytokines, whereas T cells expressing less efficient CARs such as Mz1 and Lz1
produced lower amounts of cytokines. The enhancement of cytokine levels in Lz1+P28BB T cells compared to Lz1 T cells was minimal except for interleukin (IL)-2 and IL-13. IL-2 induces proliferation and can promote either a T H 1 or T H 2 response 21 , whereas IL-13 is associated with a T H 2 response specific to 4-1BB signaling 22 . We next tested the anti-tumor activity of these T cells in animals bearing tumors expressing PSCA and/or PSMA. We inoculated mice intravenously with 2 × 10 6 GFP/Luc PC3 cells expressing PSMA, PSCA or both antigens (Supplementary Fig. 3) . Fourteen days later, we intravenously injected 1 × 10 6 Mz1+P28BB T or 1 × 10 6 Lz1+P28BB T cells into the mice. PSCA + PSMA − tumors decreased in size in recipients of Mz1+P28BB T cells but not in recipients of Lz1+P28BB T cells, confirming the inefficiency of the Lz1 CAR (Fig. 2c,d) . Similar to the CD19 CAR experiment (Fig. 1c) , PSCA + PSMA − tumors responding to Mz1 eventually relapsed and increased in size. In mice bearing PSCA + PSMA + tumor cells, however, Mz1+P28BB T cells induced robust and long-term tumor eradication. Most importantly, PSCA + PSMA + tumors were eradicated in mice treated with Lz1+P28BB T cells, resulting in complete long-term survival of all treated mice (Fig. 2d) . Tumor eradication was not induced in control mice bearing PSCA − PSMA + tumors (Fig. 2c,d) .
To thoroughly evaluate the effect of Lz1+P28BB T cells on PSCA + PSMA − tumors in animals where these T cells could be npg l e t t e r s costimulated, we analyzed the effect of Lz1+P28BB T-cell infusion on PSCA + PSMA − tumors in animals also bearing PSCA + PSMA + and PSCA − PSMA + tumors. Strikingly, Lz1+P28BB T cells eradicated PSCA + PSMA + tumors but not PSCA + PSMA − tumors (Fig. 2e) . These results demonstrate the feasibility of decreasing T-cell activation to the extent where dual CAR + CCR expressing T cells do not react against tissues expressing either the CAR-targeted antigen or the CCR-targeted antigen, and promoting T-cell activation only on encounter with the two coexpressed antigens. These data also provide proof-of-principle evidence for achieving two complementary outcomes that determine specificity and safety of T-cell tumor therapy: (i) the ability to harness combinatorial antigen recognition to design T cells specific for a tumor in the absence of a truly tumor-specific target antigen and (ii) the ability to protect cells that express only one of the targeted antigens by titrating activation and costimulatory signals so as to confine T-cell activation to sites of target antigen coexpression (Fig. 3) . This titration of CAR signals distinguishes our approach from studies that showed that two coexpressed antigen receptors boost T-cell responsiveness against double-positive cells beyond that induced by a single antigen receptor [10] [11] [12] and addresses the central problem of abolishing or reducing T-cell reactivity against single-positive tissues. Our approach ultimately parallels physiological antigen presentation and T-cell priming 23 wherein T cells are primed in lymph nodes where they receive TCR and costimulatory signals that are restricted to specialized antigen-presenting cells. T cells then migrate to peripheral sites where their activation does not depend on additional costimulation. Similarly, T cells stimulated through both a CAR and a CCR at one site may also recirculate to other peripheral sites and therein eliminate tumor cells without costimulatory dependence. However, we showed that if these sites express either the CAR target antigen or the CCR target antigen, "tumor-sensing" T cells, which exhibit carefully titrated CAR signaling, will not eradicate the single-positive tumor, which we used here as a surrogate for normal single-positive tissue. Studies in a murine syngeneic model will be conducted to validate the tumor-sensing concept in a fully immune competent model. However, these studies would have the caveats of using a mouse system to develop a human therapy that may not share the same biological and technical aspects. Notably, as CARs and CCRs recognize cell surface antigens rather than human leukocyte antigen (HLA)-peptide complexes, T cells engineered in this manner will recognize these antigens directly on the tumor but will not be costimulated by interacting with professional antigen-presenting cells that cross-present the targeted antigens in the context of HLA molecules. They also will not be activated by healthy tissues that may express a targeted antigen but do not express costimulatory ligands.
PSCA and PSMA are promising targets for the treatment of metastatic prostate cancer 24 , although neither antigen is absolutely specific to prostate tissue. PSCA is expressed in prostate tumors, and also in the renal pelvis, ureter, urinary bladder and urethra 25 . PSMA is highly expressed in metastatic prostate cancer, as well as in astrocytes type II, the kidney proximal tubule and the intestinal brush border 26 . Combinatorial PSCA/PSMA targeting is thus expected to increase prostate cancer targeting and reduce reactivity against healthy tissues expressing either antigen alone.
The "tumor-sensing" approach can be extended to other tumor types for which a combination of antigens may confer enhanced tumor specificity. For example, one may target breast cancer through combinatorial recognition of HER2, MUC1, CD44, CD49f and/or EpCAM, none of which is truly cancer-specific 27, 28 . Likewise, one may selectively target ovarian cancer through a combination of mesothelin, folate receptor-α, CD44 and/or CD133 (refs. 29,30) . When determining candidate sets of antigens for targeting a particular tumor type, an antigen should be selected based on high cell expression in cancerous tissue, but not normal tissue or lymphocytes. A second antigen should be selected so that expression of both antigens is restricted to cancerous tissue. The antigen whose expression in normal tissue would have more detrimental off-target effects should be targeted using a CCR to minimize lysis of single-positive cells. For example, HER2, MUC1 and EpCAM are not highly expressed by normal tissues and coexpression of a pair should be limited to cancerous tissue. However, because HER2 is expressed by lung epithelial cells at low levels, targeting HER2+MUC1 would be attractive by directing the CAR to MUC1 and the CCR to HER2. As many breast cancers are HER2 negative, MUC1+EpCAM may represent an attractive alternative. The targeting of tumor-initiating cells or cancer stem cells by tumor-sensing T cells represents another enticing application. Altogether, our work provides a path for restricting the selectivity and activity of engineered T cells in a manner that reconciles potency with safety.
MeTHodS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
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